Clinical Trial

Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

Study acronym: Moonlanding
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the efficacy of belzutifan in combination with pembrolizumab with or without lenvatinib in the neoadjuvant setting, followed by adjuvant pembrolizumab versus adjuvant pembrolizumab alone, as treatment for participants with intermediate-high and high risk clear cell renal cell carcinoma (ccRCC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-11.
Trial Details
NCT Number NCT07593040
Lead Sponsor Vall d'Hebron Institute of Oncology
Conditions Renal Cell Carcinoma
Enrollment 150 participants
Start Date 2026-06
Primary Completion 2028-01 (estimated)
Study Completion 2031-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-20